222 related articles for article (PubMed ID: 33392303)
41. The Influence of Gut Microbial Species on Diabetes Mellitus.
Al-Ishaq RK; Samuel SM; Büsselberg D
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175825
[TBL] [Abstract][Full Text] [Related]
42. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota.
Forslund K; Hildebrand F; Nielsen T; Falony G; Le Chatelier E; Sunagawa S; Prifti E; Vieira-Silva S; Gudmundsdottir V; Pedersen HK; Arumugam M; Kristiansen K; Voigt AY; Vestergaard H; Hercog R; Costea PI; Kultima JR; Li J; Jørgensen T; Levenez F; Dore J; ; Nielsen HB; Brunak S; Raes J; Hansen T; Wang J; Ehrlich SD; Bork P; Pedersen O
Nature; 2015 Dec; 528(7581):262-266. PubMed ID: 26633628
[TBL] [Abstract][Full Text] [Related]
43. The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: new insights into old diseases.
Pascale A; Marchesi N; Govoni S; Coppola A; Gazzaruso C
Curr Opin Pharmacol; 2019 Dec; 49():1-5. PubMed ID: 31015106
[TBL] [Abstract][Full Text] [Related]
44. Dietary Epigallocatechin-3-Gallate Alters the Gut Microbiota of Obese Diabetic
Park JM; Shin Y; Kim SH; Jin M; Choi JJ
J Med Food; 2020 Oct; 23(10):1033-1042. PubMed ID: 33054538
[TBL] [Abstract][Full Text] [Related]
45. Type 2 diabetes mellitus associated with increased risk for colorectal cancer: evidence from an international ecological study and population-based risk analysis in China.
Ren X; Zhang X; Zhang X; Gu W; Chen K; Le Y; Lai M; Zhu Y
Public Health; 2009 Aug; 123(8):540-4. PubMed ID: 19664792
[TBL] [Abstract][Full Text] [Related]
46. The diversity of gut microbiota in type 2 diabetes with or without cognitive impairment.
Zhang Y; Lu S; Yang Y; Wang Z; Wang B; Zhang B; Yu J; Lu W; Pan M; Zhao J; Guo S; Cheng J; Chen X; Hong K; Li G; Yu Z
Aging Clin Exp Res; 2021 Mar; 33(3):589-601. PubMed ID: 32301029
[TBL] [Abstract][Full Text] [Related]
47. Association of
Elahi Z; Shariati A; Bostanghadiri N; Dadgar-Zankbar L; Razavi S; Norzaee S; Vazirbani Arasi S; Darban-Sarokhalil D
Heliyon; 2023 Dec; 9(12):e22602. PubMed ID: 38089982
[TBL] [Abstract][Full Text] [Related]
48. Role of SCFAs in gut microbiome and glycolysis for colorectal cancer therapy.
Wang G; Yu Y; Wang YZ; Wang JJ; Guan R; Sun Y; Shi F; Gao J; Fu XL
J Cell Physiol; 2019 Aug; 234(10):17023-17049. PubMed ID: 30888065
[TBL] [Abstract][Full Text] [Related]
49. Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial.
Lee SE; Choi Y; Jun JE; Lee YB; Jin SM; Hur KY; Ko GP; Lee MK
Diabetes Metab J; 2019 Aug; 43(4):422-431. PubMed ID: 31237126
[TBL] [Abstract][Full Text] [Related]
50. Abnormal gut microbiota composition contributes to the development of type 2 diabetes mellitus in db/db mice.
Yu F; Han W; Zhan G; Li S; Jiang X; Wang L; Xiang S; Zhu B; Yang L; Luo A; Hua F; Yang C
Aging (Albany NY); 2019 Nov; 11(22):10454-10467. PubMed ID: 31760385
[TBL] [Abstract][Full Text] [Related]
51. Role of Microbiome in Carcinogenesis Process and Epigenetic Regulation of Colorectal Cancer.
Farhana L; Banerjee HN; Verma M; Majumdar APN
Methods Mol Biol; 2018; 1856():35-55. PubMed ID: 30178245
[TBL] [Abstract][Full Text] [Related]
52. Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly diagnosed type 2 diabetes patients.
Elbere I; Silamikelis I; Dindune II; Kalnina I; Ustinova M; Zaharenko L; Silamikele L; Rovite V; Gudra D; Konrade I; Sokolovska J; Pirags V; Klovins J
PLoS One; 2020; 15(10):e0241338. PubMed ID: 33125401
[TBL] [Abstract][Full Text] [Related]
53. Enterotype-based Analysis of Gut Microbiota along the Conventional Adenoma-Carcinoma Colorectal Cancer Pathway.
Yang TW; Lee WH; Tu SJ; Huang WC; Chen HM; Sun TH; Tsai MC; Wang CC; Chen HY; Huang CC; Shiu BH; Yang TL; Huang HT; Chou YP; Chou CH; Huang YR; Sun YR; Liang C; Lin FM; Ho SY; Chen WL; Yang SF; Ueng KC; Huang HD; Huang CN; Jong YJ; Lin CC
Sci Rep; 2019 Jul; 9(1):10923. PubMed ID: 31358825
[TBL] [Abstract][Full Text] [Related]
54. Huang-Lian-Jie-Du-Decoction Ameliorates Hyperglycemia and Insulin Resistant in Association With Gut Microbiota Modulation.
Chen M; Liao Z; Lu B; Wang M; Lin L; Zhang S; Li Y; Liu D; Liao Q; Xie Z
Front Microbiol; 2018; 9():2380. PubMed ID: 30349514
[No Abstract] [Full Text] [Related]
55. New insights into natural products that target the gut microbiota: Effects on the prevention and treatment of colorectal cancer.
Lu L; Dong J; Liu Y; Qian Y; Zhang G; Zhou W; Zhao A; Ji G; Xu H
Front Pharmacol; 2022; 13():964793. PubMed ID: 36046819
[TBL] [Abstract][Full Text] [Related]
56. Dietary Factors in the Control of Gut Homeostasis, Intestinal Stem Cells, and Colorectal Cancer.
Francescangeli F; De Angelis ML; Zeuner A
Nutrients; 2019 Dec; 11(12):. PubMed ID: 31816977
[TBL] [Abstract][Full Text] [Related]
57. Combination of Oligofructose and Metformin Alters the Gut Microbiota and Improves Metabolic Profiles, Contributing to the Potentiated Therapeutic Effects on Diet-Induced Obese Animals.
Li Q; He R; Zhang F; Zhang J; Lian S; Liu H
Front Endocrinol (Lausanne); 2019; 10():939. PubMed ID: 32158428
[TBL] [Abstract][Full Text] [Related]
58. In vivo pharmacodynamic and pharmacokinetic effects of metformin mediated by the gut microbiota in rats.
Wu B; Chen M; Gao Y; Hu J; Liu M; Zhang W; Huang W
Life Sci; 2019 Jun; 226():185-192. PubMed ID: 30953641
[TBL] [Abstract][Full Text] [Related]
59. Response of gut microbiota in type 2 diabetes to hypoglycemic agents.
Zhang F; Wang M; Yang J; Xu Q; Liang C; Chen B; Zhang J; Yang Y; Wang H; Shang Y; Wang Y; Mu X; Zhu D; Zhang C; Yao M; Zhang L
Endocrine; 2019 Dec; 66(3):485-493. PubMed ID: 31410749
[TBL] [Abstract][Full Text] [Related]
60. Effects of synbiotic supplementation on gut microbiome, serum level of TNF-α, and expression of microRNA-126 and microRNA-146a in patients with type 2 diabetes mellitus: study protocol for a double-blind controlled randomized clinical trial.
Zeinali F; Aghaei Zarch SM; Vahidi Mehrjardi MY; Kalantar SM; Jahan-Mihan A; Karimi-Nazari E; Fallahzadeh H; Hosseinzadeh-Shamsi-Anar M; Rahmanian M; Fazeli MR; Mozaffari-Khosravi H
Trials; 2020 Apr; 21(1):324. PubMed ID: 32290852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
